Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956937 | 0.91 | CTSK (0.42) | EPHX1CTSKALDH1A1TSHRCYP3A4 | |
| SCHEMBL5956907 | 0.91 | EPHX1 (0.44) | EPHX1CTSKALDH1A1TSHRGAA | |
| SCHEMBL5956600 | 0.87 | ALDH1A1 (0.43) | CTSKALDH1A1TSHRCYP3A4MAPT | |
| SCHEMBL5956683 | 0.87 | ALDH1A1 (0.43) | CTSKALDH1A1TSHRCYP3A4MAPT | |
| SCHEMBL5956644 | 0.87 | ALDH1A1 (0.43) | CTSKALDH1A1TSHRCYP3A4MAPT | |
| SCHEMBL5956900 | 0.83 | ALDH1A1 (0.43) | EPHX1CTSKALDH1A1TSHRGAA | |
| SCHEMBL5956624 | 0.83 | POLB (0.47) | — | |
| SCHEMBL5956699 | 0.82 | KMT2A (0.51) | ALDH1A1CA1CA2ACHEKMT2A | |
| SCHEMBL5956515 | 0.80 | MEN1 (0.48) | EPHX1CTSKALDH1A1TSHRCYP3A4 | |
| SCHEMBL1590956 | 0.80 | CA1 (0.51) | CTSKALDH1A1TSHRCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | EPHX1 977/4885CTSK 635/4885ALDH1A1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.